2BROWN M. A vaccine against atherosclerosis[J].Drug Discov Today, 2002,7 : 588- 590.
3CHYU K Y, ZHAO X, REYES O S,et al. Immunization using an ApoB-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apoE(-/-)mice[J]. Biochem Biophys Res Commun, 2005,338: 1982- 1989.
4RITTERSHAUS C W, MILLER D P, THOMAS LJ. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis Arterioscler[J]. Thromb Vasc Biol,2000,20:2106-2112.
5GAOFU Q ,DAN M, JIE W, et al. Long -lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants[J]. Vaccine, 2004,22: 3187-3194.
6GAOFU Q,JUN L,XIN Y,et al. Vaccinating rabbits with a cholesteryl ester transfer protein B-cell epitope carried by heat shock protein-65 for inducing anti-CETP antibodies and reducing aortic lesions in vivo[J]. J Cardiovasc Pharmacol, 2005, 45:591-598.
7MICHAEL H D,KEVIN M,DENISE U, et al. The safe and immunogenicity of a CETP in healthy adults[J]. Atherosclerosis, 2003,169 : 113- 120.
8ANDRE P, NANNIZZI ALAIMO L, Phillips D R.Platelet-derived CD40L: the switch hitting player of cardiovascular disease[J]. Circulation, 2002,106: 896-899.
9WU M, LI Y G. The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats[J]. Mol Cell Biochem, 2006,282 : 141 -146.
10LUTGENS E, GLEUTJENS K B, HEENE S, et al.Both early and delayed anti- CD40L antibody treatment induces a stable plaque phenotype[J]. Proc.Natl. Acad Sci. USA,2000,97:7464-7469.
2Lusis AJ. Atherosclerosis. Nature, 2000. 407: 233-241.
3Zhu J, Quyyumi AA, Norman JE, et al. The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis, 2000,182:1583-1587.
4Meier CR, Jick SS, Derby LE, et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet, 1998, 351:1467-1471.
5Epsein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation, 1999, 100:e20- e 28.
6Rupprecht HJ, Blankenberg S, Bickel C, et al. impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation, 2001,104:25-31.
7Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol, 2000,85:140-146.
8Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ, 2000, 321:208-213.
9Whincup P, Danesh J, Walker M, et al. Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-aged men. Circulation, 2000,101:1647-1652.
10Fu M L, Herlitz H, Wallukat G, et al. Non-desensi tized positive chronotropic effect of anti-angiotension Ⅱ receptor autoantibodies in patient with malignant hypertension. Circulation, 1996,94:4046(Abstr).
